Figure 6
D-series resolvins RvD1 and aspirin-triggered RvD1 (AT-RvD1) increase in [Ca2+]i, in conjunctival goblet cells. Increase in [Ca2+]i using fura-2 loaded rat conjunctival goblet cells stimulated by RvD1 and AT-RvD1. (a) Pseudo color images of [Ca2+]i in single goblet cells stimulated by RvD1 (top panels) or AT-RvD1 (bottom panels). (b) Intracellular [Ca2+]i over time in response to RvD1 (10−9 M), AT-RvD1 (10−8 M), or histamine (His; 10−5 M) from a representative experiment (top panel), and peak [Ca2+]i response to increasing concentrations of RvD1 (open circles) and AT-RvD1 (closed circles) from four experiments are shown in bottom panel. *P<0.05 (vehicle vs. resolvin). (c) Peak [Ca2+]i in response to RvD1 (left panel) and AT-RvD1 (right panel) in the presence (closed circles) and absence (open circles) of extracellular Ca2+ from three experiments, *P<0.05 (resolvin in presence vs. absence of extracellular Ca2+). (d, e) Peak [Ca2+]i in response to thapsigargin (10−6 M) added either before or after RvD1 (10−8 M) in the presence (left panel of d) or absence (right panel of d) of extracellular Ca2+ or before or after AT-RvD1 (10−8 M) addition in the absence of extracellular Ca2+ (e). (f, g) Mean response of [Ca2+]i over time from three experiments to RvD1 (f) and AT-RvD1 (g) in fura-2 loaded conjunctival goblet cells treated with transfection reagent only (control), a scrambled sequence small interfering RNA (sc siRNA), or lipoxin A4 receptor (ALX/FPR2) siRNA. (h) Mean of peak [Ca2+]i from three experiments.
